Articles from Kovina Therapeutics Inc.

Kovina Therapeutics Inc., a biotechnology company developing first-in-class small molecule therapeutics targeting the Human Papillomavirus (HPV) E6 oncoprotein, today announced a $2.3 million Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI). The two-year award will support IND-enabling development of Kovina’s lead oral small molecule program for HPV-driven cancers.

Kovina Therapeutics Inc. today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of research validating its HPV E6 targeted therapeutic approach.

Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections. The award provides approximately $275,000 with the opportunity for advancement to Phase 2.

Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Allergy and Infectious Diseases (NIAID)/NIH to treat Human Papillomavirus (HPV) premalignant infections. The award provides approximately $300,000 with the opportunity for advancement to Phase 2.

Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute/NIH. With successful achievement of its milestones, the award will transition to a Small Business Innovation Research (SBIR) award and will provide approximately $2,400,000 over three years.